X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The license agreement provides InxMed with right to use EZWi-Fit® platform for the development of the next generation tumor-associated antigens targeting ADCs. InxMed will have the right for development, manufacturing, and commercialization of these ADC candidate molecules.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Escugen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 19, 2023
Details:
OMTX705 is a novel antibody–drug conjugate (ADC) molecule targeting fibroblast-activating protein alpha, which is investigated for the treatment of hard-to-treat solid tumors.
Lead Product(s): OMTX705
Therapeutic Area: Oncology Product Name: OMTX705
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
Under the agreement, GeneQuantum will provide InxMed with its globally leading technologies in site-specific glycan conjugation, stable linker small molecule technology, and intelligent continuous conjugation production platform for developing innovative ADC drugs.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: GeneQuantum Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 17, 2023
Details:
The data showed that patients receiving combination of IN10018 (BI 853520) with PLD demonstrated promising antitumor activities and manageable safety profile in PROC patients, with a high overall response rate (ORR) of 56.7%.
Lead Product(s): IN10018,Pegylated Liposomal Doxorubicin
Therapeutic Area: Oncology Product Name: BI 853520
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
InxMed will use the funds to accelerate ongoing clinical trials of IN10018 (BI 853520) for multiple cancer types in both US and China, including the initiation of pivotal trials, and advance more stroma targeting pipelines into clinics in both US and China.
Lead Product(s): IN10018,Cobimetinib
Therapeutic Area: Oncology Product Name: BI 853520
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hyfinity Investments
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 09, 2022
Details:
Early clinical data on IN10018,a highly-selective adenosine triphosphate competitive FAK inhibitor showed its safety and efficacy in multiple tumor types, and latest research results and preclinical data demonstrated that IN10018 can also be effective in combination therapies.
Lead Product(s): BI 853520,PEG-Liposomal Doxorubicin
Therapeutic Area: Oncology Product Name: IN10018
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2022
Details:
IN10018, formerly known as BI853520, is a potent and selective ATP-competitive focal adhesion kinase (FAK) small molecule inhibitor under clinical development stage in United States, Australia, and China.
Lead Product(s): BI 853520
Therapeutic Area: Oncology Product Name: IN10018
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2021
Details:
Early clinical data of IN10018 has demonstrated a favorable safety profile and promising efficacy signals against a number of tumor types.
Lead Product(s): IN10018,Undisclosed
Therapeutic Area: Oncology Product Name: BI 853520
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2021
Details:
Funding will support the acceleration of IN10018 clinical program and expand InxMed's portfolio. IN10018 is a potent and selective ATP-competitive focal adhesion kinase small molecule inhibitor.
Lead Product(s): IN10018,Cobimetinib
Therapeutic Area: Oncology Product Name: BI 853520
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ennovation Ventures
Deal Size: $19.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 03, 2020
Details:
The combination of KRAS G12C inhibitors and IN10018 induced FAK signaling by KRAS G12C inhibition, serving as one predominant mechanism of drug resistance of KRAS G12C inhibition, and IN10018 significantly decreases the FAK signaling induced by KRAS G12C inhibition.
Lead Product(s): IN10018,Cobimetinib
Therapeutic Area: Oncology Product Name: IN10018
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
